Myra Vision, A Shifamed Portfolio Company, Closes $17M In Series A Financings

Myra Vision, a Shifamed portfolio company, announced today the closing of its $17M Series A financings, which will be used to advance product development, scale infrastructure, and expand their team in order to support the development of the first of its kind glaucoma treatment device. The financings were led by The Capital Partnership (TCP), with participation from Cormorant Asset Management and Shifamed angel investors. In conjunction with the financing, the company has changed its name to Myra Vision, Inc. from Myra Medical, Inc.